Breast Cancer Clinical Trials in Baltimore

Showing 301-320 of 691 trials

PRS-343 in HER2-Positive Solid Tumors

NCT03330561

A multi center, open-label, Phase 1 dose escalation study with expansion cohort is designed to determine the MTD, RP2D and dosing schedule of PRS-343 in patients with HER2+ advanced or metastatic solid tumors.

HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Bladder Cancer+1 more

Pieris Pharmaceuticals, Inc.85 participantsStarted Sep 2017

Tucson, Arizona, United States • Santa Monica, California, United States • Washington D.C., District of Columbia, United States +7 more locations

COMPLETEDPhase 3< 1 mile

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

NCT01942135

The study is a randomized, double blind, placebo controlled, Phase 3 clinical trial with the primary objective of demonstrating the superiority of palbociclib in combination with fulvestrant (Faslodex®) over fulvestrant alone in prolonging PFS in women with HR+, HER2 negative metastatic breast cancer whose disease has progressed after prior endocrine therapy. The safety between the two treatment arms will also be compared. During study treatment, pre- and perimenopausal women must be receiving therapy with the LHRH agonist goserelin (Zoladex® or generic).

Metastatic Breast Cancer

Pfizer521 participantsStarted Sep 2013

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +244 more locations

PRS-343 in HER2-Positive Solid Tumors

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

Breast Cancer Trials in Other Cities

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes

A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer

Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

The Treatment of Stage I and II Carcinoma of the Breast With Mastectomy and Axillary Dissection Versus Excisional Biopsy, Axillary Dissection, and Definitive Irradiation

Non-Viral TCR Gene Therapy

Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk

A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Other Conditions in Baltimore